179 related articles for article (PubMed ID: 15385105)
1. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
Brustmann H
Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
Brustmann H; Naudé S
Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
[TBL] [Abstract][Full Text] [Related]
4. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
6. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
Brustmann H
Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
[TBL] [Abstract][Full Text] [Related]
7. Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study.
Brustmann H
Gynecol Oncol; 2004 Jan; 92(1):268-76. PubMed ID: 14751170
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining.
Garzetti GG; Ciavattini A; Lucarini G; Pugnaloni A; De Nictolis M; Amati S; Romanini C; Biagini G
Gynecol Oncol; 1999 Jun; 73(3):396-401. PubMed ID: 10366466
[TBL] [Abstract][Full Text] [Related]
9. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E
Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598
[TBL] [Abstract][Full Text] [Related]
10. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.
Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S
J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
12. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
13. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study.
Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
J Med Assoc Thai; 2009 Mar; 92(3):308-14. PubMed ID: 19301721
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
15. [Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma].
Shi HR; Song WJ; Chen ZM; Wu QH
Ai Zheng; 2005 Sep; 24(9):1127-31. PubMed ID: 16159439
[TBL] [Abstract][Full Text] [Related]
16. [Expressions of VEGF/VEGFRs and activation of STATs in ovarian carcinoma].
Chen BY; Ye DF; Xie X; Chen HZ; Lü WG
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):33-7. PubMed ID: 15771796
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
19. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma.
Chen H; Ye D; Xie X; Chen B; Lu W
Gynecol Oncol; 2004 Sep; 94(3):630-5. PubMed ID: 15350351
[TBL] [Abstract][Full Text] [Related]
20. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
